Moreover, companies would have an incentive to produce and distribute drugs at the lowest possible price, because only when the poor could use them would the drug save the greatest possible number of lives. A company might choose to allow cheap generic copies of its drug to be made in developing countries, because that would enable it to be used more widely, and to save more lives – for which the Health Impact Fund would reward the company that registered it.